Eye scanner may predict dangerous brain side effects in cancer treatment
NCT ID NCT06144151
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study tests whether a non-invasive handheld device that measures pupil size and reactivity can predict neurological side effects in patients receiving CAR-T cell therapy for lymphoma. Researchers will monitor 100 adults before and after treatment to see if pupil changes signal the onset of neurotoxicity. The goal is to find a simple, early warning tool to improve patient safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, quick test to predict and prevent serious brain side effects from CAR-T therapy.
- What could go wrong
- This is a small pilot study, so results may not apply to all patients. The pupil test might not reliably predict neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?